PLUS1
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 41.76 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| REGENXBIO Inc | RGNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.95 | -2.22% | 41.76 | 42.87 | 41.12 | 42.62 | 42.71 | 00:00:04 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 34.04 | 45.90 | 11.86 | 25.84% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,003 | 539,793 | $ 41.82 | $ 22,573,671 | 535,764 | 30.38 - 63.21 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:08:17 | average | 971 | $ 41.76 | USD |
REGENXBIO Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 1.54B | 36.87M | $ 99.94M | 2.84 | -7.08 | 36.36M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 2.00 | 1.40% |
REGENXBIO News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/26/2019 | 07:00 | PR Newswire (US) | REGENXBIO to Present at the Evercore ISI 2nd Annual.. |
| 11/05/2019 | 16:24 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/05/2019 | 16:12 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/05/2019 | 16:05 | PR Newswire (US) | REGENXBIO Reports Third Quarter 2019 Financial and Operating.. |
| 10/30/2019 | 07:05 | GlobeNewswire Inc. | Clearside Biomedical Announces Option Exercise by REGENXBIO.. |
| 10/29/2019 | 07:00 | PR Newswire (US) | REGENXBIO To Host Conference Call on November 5 to Discuss.. |
| 10/17/2019 | 07:00 | PR Newswire (US) | REGENXBIO Announces Presentations at the European Society of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGNX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 43.20 | 45.88 | 41.12 | 44.08 | 700,056 | -1.44 | -3.33% |
| 1 Month | 38.59 | 45.88 | 35.88 | 40.88 | 506,272 | 3.17 | 8.21% |
| 3 Months | 39.56 | 45.88 | 33.04 | 38.39 | 531,026 | 2.20 | 5.56% |
| 6 Months | 49.16 | 55.23 | 30.38 | 40.75 | 531,994 | -7.40 | -15.05% |
| 1 Year | 51.70 | 63.21 | 30.38 | 45.03 | 540,997 | -9.94 | -19.23% |
| 3 Years | 21.45 | 85.10 | 16.30 | 44.02 | 439,268 | 20.31 | 94.69% |
| 5 Years | 30.26 | 85.10 | 7.0701 | 40.43 | 359,310 | 11.50 | 38.0% |
REGENXBIO Description
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |
